Publication: Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome
Accepted Date
2012-09-06
Issued Date
2013-07-15
Copyright Date
2013
Resource Type
Language
eng
ISSN
1972-2680 (electronic)
2036-6590 (printed)
2036-6590 (printed)
Rights
Mahidol University
Rights Holder(s)
Journal of infection in developing countries
Bibliographic Citation
Aung MN, Leowattana W, Win KN, Tangpukdee N, Muangnoicharoen S. Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome. J Infect Dev Ctries. 2013 Jul 15;7(7):541-9.
Suggested Citation
Aung, Myo Nyein, Wattana Leowattana, วัฒนา เลี้ยววัฒนา, Win, Khine Nwe, Noppadon Tangpukdee, นพดล ตั้งภักดี, Sant Muangnoicharoen, สัณฑ์ ม่วงน้อยเจริญ Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome. Aung MN, Leowattana W, Win KN, Tangpukdee N, Muangnoicharoen S. Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome. J Infect Dev Ctries. 2013 Jul 15;7(7):541-9.. doi:10.3855/jidc.2759 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/856
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome
Corresponding Author(s)
Abstract
INTRODUCTION: Chronic hepatitis B (CHB) is a globally common infectious disease.
Its clinical course is complicated. In Southeast Asia, nucleos(t)ide analogues
(NA) are commonly used drugs for CHB treatment. Composite treatment outcome has
often been used in CHB clinical practice, but rarely predicted epidemiologically.
This study aimed to compare the composite treatment outcome between CHB patients
with low and high treatment-naïve viral load, and to identify its predictors
METHODOLOGY: This retrospective cohort study followed up 95 CHB patients on NA
treatment for a year. Composite treatment outcome was defined as undetectable HBV
DNA level, ALT normalization and, HBeAg clearance in the case of HBeAg-positive
patients. Multinomial logistic regression analysis was applied to analyze the
significant treatment response predictors.
RESULTS: Complete composite treatment outcome was achieved by 52% of CHB patients
with an initial viral load < 6.5 log 10 copies /ml, but 31% of those had an
initial viral load ≥ log 6.5 log 10 copies /ml. Outcome was predicted by HBeAg
negativity (adjusted relative risk ratio, aRRR = 11.1, 95 % confidence interval,
CI 3-41.3) and ALT normalization within the sixth month of therapy (aRRR = 6.7,
CI 1.8-24.9). An elevation of ALT to more than 1.5 times the normal value (40
IU/ml) can lead to an incomplete response on NA therapy (aRRR = 6.2, CI
1.5-26.6.)
CONCLUSION: Routine clinical markers other than pre-treatment viral load
predicted composite CHB outcome on NA Therapy.